Are we seeing the light at the end of the tunnel for high lipoprotein(a)?


Meral Kayikcioglu
Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey
Hasan Selcuk Ozkan
Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey
Lale Tokgozoglu
Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey


Lipoprotein (a) (Lp(a)) attests to be of interest as a new lipoprotein target. However, Lp(a) was discovered in 1963 and since then was recognized as a low-density lipoprotein (LDL)-like lipoprotein with a structurally similar domain to plasminogen. We are increasingly recognizing the importance of Lp(a) and cardiovascular pathologies including atherosclerotic cardiovascular disease, aortic valve stenosis, heart failure, and atrial fibrillation. However, we neither have a standardized measurement method nor an appropriate agent to intervene with this old threat that we have recognized for more than 50 years. Herein, we present an up-to-date review of our knowledge about Lp(a) covering measurement methods, its associates, and summary of the currently available therapies and emerging therapeutic agents for the management of high Lp(a) in the light of recent evidence and guideline recommendations


  1. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132–7.
  2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan;41(1):111–88.
  3. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct;43(39):3925–46.
  4. Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022 May;349:72–81.
  5. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): Insights into lipoprotein(a) assembly and pathogenicity. Vol. 15, Current Opinion in Lipidology. Curr Opin Lipidol; 2004. p. 167–74.
  6. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a). Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003 Jul;278(26):23260–9.
  7. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J Lipid Res. 2016 Nov;57(11):1953–75.
  8. Di Maio S, Lamina C, Coassin S, Forer L, Würzner R, Schönherr S, et al. Lipoprotein(a) and SARS-CoV-2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events. J Intern Med. 2022 Jan;291(1):101–7.
  9. Dzobo KE, Kraaijenhof JM, Stroes ESG, Nurmohamed NS, Kroon J. Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis. 2022 May;349:101–9.
  10. Schnitzler JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, Van Weeghel M, et al. Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circ Res. 2020 May;126(10):1346–59.
  11. Liu Z, Li Y, Wang Y, Liu Z, Su Y, Ma Q, et al. Lipoprotein(a), an Opsonin, Enhances the Phagocytosis of Nontypeable Haemophilus influenzae by Macrophages. Ortega E, editor. J Immunol Res. 2021 Nov;2021:1–14.
  12. Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis. 2022 May;349:17–35.
  13. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993 Feb;91(2):443–7.
  14. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Császár A, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607–14.
  15. de Boer LM, Hof MH, Wiegman A, Stroobants AK, Kastelein JJP, Hutten BA. Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. Atherosclerosis. 2022 May;349:227–32.
  16. Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009 Apr;119(13):1711–9.
  17. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan;125(2):241–9.
  18. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022 May;349:53–62.
  19. Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2239–45.
  20. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight. Am J Epidemiol. 2009 Jun;169(11):1352–61.
  21. Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014 Apr;18(2):234–7.
  22. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995 Jul;6(1):110–20.
  23. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb Vasc Biol. 1994 Sep;14(9):1399–404.
  24. Connolly CM, Li J, Goldman D, Fava A, Magder L, Petri M. Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function. Lupus. 2022 Oct;31(11):1367–72.
  25. Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015 May;56(5):1034–42.
  26. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010 Dec;5(12):e14328.
  27. Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, et al. Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women’s Interagency HIV Study. J Lipid Res. 2018 Oct;59(10):1967–76.
  28. Lippi G, Szergyuk I, de Oliveira MHS, Benoit SW, Benoit JL, Favaloro EJ, et al. The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury. J Thromb Thrombolysis. 2021 Oct;
  29. Kaltoft M, Glavind KS, Nielsen SF, Langsted A, Iversen KK, Nordestgaard BG, et al. Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality. Atherosclerosis. 2022 Sep;357:33–40.
  30. Melita H, Manolis AA, Manolis TA, Manolis AS. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. Vol. 79, Journal of cardiovascular pharmacology. J Cardiovasc Pharmacol; 2022. p. e18–35.
  31. Lin YK, Yeh CT, Kuo KT, Fong IH, Yadav VK, Kounis NG, et al. Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory α 7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm. Oxid Med Cell Longev. 2022;2022:9964689.
  32. Kamstrup PR. Lipoprotein(a) and ischemic heart disease-A causal association? A review. Vol. 211, Atherosclerosis. 2010. p. 15–23.
  33. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation. 2008 Jan;117(2):176–84.
  34. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012 Aug;60(8):722–9.
  35. Shi YP, Cao YX, Jin JL, Liu HH, Zhang HW, Guo YL, et al. Lipoprotein(a) as a predictor for the presence and severity of premature coronary artery disease: A cross-sectional analysis of 2433 patients. Coron Artery Dis. 2020;32(1):78–83.
  36. Huded CP, Shah NP, Puri R, Nicholls SJ, Wolski K, Nissen SE, et al. Association of serum lipoprotein (A) levels and coronary atheroma volume by intravascular ultrasound. J Am Heart Assoc. 2020 Dec;9(23):e018023.
  37. Chung YH, Lee BK, Kwon HM, Min PK, Choi EY, Yoon YW, et al. Coronary calcification is associated with elevated serum lipoprotein (a) levels in asymptomatic men over the age of 45 years: A cross-sectional study of the Korean national health checkup data. Medicine (Baltimore). 2021 Mar;100(9):e24962.
  38. Cho JH, Lee DY, Lee ES, Kim J, Park SE, Park CY, et al. Increased risk of coronary artery calcification progression in subjects with high baseline Lp(a) levels: The Kangbuk Samsung Health Study. Int J Cardiol. 2016 Nov;222:233–7.
  39. Cao YX, Zhang HW, Jin JL, Liu HH, Zhang Y, Zhang M, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thromb Haemost. 2020 Dec;
  40. Zhang Y, Jin JL, Cao YX, Liu HH, Zhang HW, Guo YL, et al. Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: A prospective, large cohort study. J Transl Med. 2020 Oct;18(1).
  41. Xu W, Guan H, Gao D, Wang Z, Ba Y, Yang H, et al. The association of syntax score with levels of lipoprotein(A) and inflammatory biomarkers in patients with stable coronary artery disease and different low-density lipoprotein cholesterol levels. Diabetes, Metab Syndr Obes Targets Ther. 2020;13:4297–310.
  42. Pokrovsky SN, Ezhov M V., Il’Ina LN, Afanasieva OI, Sinitsyn VY, Shiriaev AA, et al. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003 Oct;126(4):1071–5.
  43. Huang Z, Shui X, Ling Y, Zhou L, Shi W, Luo Y, et al. Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2021 Feb;44(2):176–85.
  44. Tao J, Dai W, Ye C, Yao Q, Zhou M, Li Y. Preprocedural Lp(a) level and ApoB/ApoA-Ι ratio and the risk for contrast-induced acute kidney injury in patients undergoing emergency PCI. Lipids Health Dis. 2021 Dec;20(1).
  45. Li Q, Chen Y, Yu L, Zhu L, Wang Z, Jiao S, et al. The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease. Atherosclerosis. 2022 May;349:204–10.
  46. Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, et al. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42(7):1312–8.
  47. Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases ― revisited ―. Vol. 84, Circulation Journal. Japanese Circulation Society; 2020. p. 867–74.
  48. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014 Feb;63(5):470–7.
  49. Kaltoft M, Sigvardsen PE, Afzal S, Langsted A, Fuchs A, Kühl JT, et al. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study. Atherosclerosis. 2022 May;349:166–74.
  50. Hovland A, Narverud I, Lie Øyri LK, Bogsrud MP, Aagnes I, Ueland T, et al. Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. J Clin Lipidol. 2020 Jan;15(1).
  51. Pérez de Isla L, Watts GF, Alonso R, Díaz-Díaz JL, Muñiz-Grijalvo O, Zambón D, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021 Jan;
  52. Yang Y, Hong Y, Yang W, Zheng Z. Association of lipoprotein(a) with aortic dissection. Clin Cardiol. 2022 Sep;45(9):908.
  53. Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Hear Fail. 2016 Jan;4(1):78–87.
  54. Wu B, Zhang Z, Long J, Zhao H, Zeng F. Association between lipoprotein (a) and heart failure with reduced ejection fraction development. J Clin Lab Anal. 2022 Jan;36(1):e24083.
  55. Li Z, Liu J, Shen J, Chen Y, He L, Li M, et al. Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction. ESC Hear Fail. 2022 Aug;9(4):2399—2406.
  56. Sakata K, Kumakura H, Funada R, Matsuo Y, Nakashima K, Iwasaki T, et al. Lipoprotein(a) is a Promising Residual Risk Factor for Long-Term Clinical Prognosis in Peripheral Arterial Disease. Ann Vasc Dis. 2022 Sep;15(3):186–92.
  57. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019 Aug;25(8):1274–9.
  58. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, et al. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy. Atherosclerosis. 2022 May;349:196–203.
  59. Jun JE, Kang H, Hwang YC, Ahn KJ, Chung HY, Jeong IK. The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study. Diabetes Res Clin Pract. 2021 Jan;171.
  60. Ishii D, Zanaty M, Roa JA, Li L, Lu Y, Sabotin R, et al. Concentration of Lp(a) (Lipoprotein[a]) in Aneurysm Sac Is Associated With Wall Enhancement of Unruptured Intracranial Aneurysm. Stroke. 2021 Feb;STROKEAHA120032304.
  61. Arnold M, Schweizer J, Nakas CT, Schütz V, Westphal LP, Inauen C, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021 Mar;
  62. Waissi F, Dekker M, Timmerman N, Hoogeveen RM, Van Bennekom J, Dzobo KE, et al. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients following Carotid Endarterectomy. Stroke. 2020;51(10):2972–82.
  63. Mohammadi-Shemirani P, Chong M, Narula S, Perrot N, Conen D, Roberts JD, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022 Apr;79(16):1579–90.
  64. Ding WY, Protty MB, Davies IG, Lip GYH. Relationship between lipoproteins, thrombosis, and atrial fibrillation. Cardiovasc Res. 2022 Feb;118(3):716–31.
  65. Konrad E, Güralp O, Shaalan W, Elzarkaa AA, Moftah R, Alemam D, et al. Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study. J Obstet Gynaecol (Lahore). 2020 Jan;40(1):53–8.
  66. Jakimovski D, Zivadinov R, Pelizzari L, Browne RW, Weinstock-Guttman B, Ramanathan M. Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. J Vasc Res. 2020 Jan;57(1):16–23.
  67. Faruq RN, D’Silva P, Lau FD, Zhao C, Majumdar S. Early-Onset Vascular Dementia in a 43-Year-Old Man with Accelerated Atherosclerotic Disease, Elevated Lipoprotein (a), and a Missense DNAJC5 Variant with Potential Association to Adult-Onset Ceroid Lipofuscinosis. Case Rep Neurol. 2021 Aug;13(2):565–71.
  68. Choe C un, Petersen E, Lezius S, Cheng B, Schulz R, Buhmann C, et al. Association of lipid levels with motor and cognitive function and decline in advanced Parkinson’s disease in the MARK-PD study. Parkinsonism Relat Disord. 2021 Apr;85(February 2020):5–10.
  69. Moosaie F, Davatgari RM, Firouzabadi FD, Esteghamati S, Deravi N, Meysamie A, et al. Lipoprotein(a) and Apolipoproteins as Predictors for Diabetic Retinopathy and Its Severity in Adults With Type 2 Diabetes: A Case-Cohort Study. Can J Diabetes. 2020 Jul;44(5):414–21.
  70. Shao M, Li Y, Teng J, Li S, Cao W. Association Between Serum Lipid Levels and Patients With Primary Angle-Closure Glaucoma in China: A Cross Sectional, Case–Control Study. Front Med. 2021 Feb;8:618970.
  71. Chubykina U V, Ezhov M V, Afanasieva OI, Klesareva EA, Pokrovsky SN. Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis. Dis (Basel, Switzerland). 2022 Jan;10(1).
  72. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018;71(2):177–92.
  73. Meroni M, Longo M, Lombardi R, Paolini E, Macchi C, Corsini A, et al. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2021;
  74. Feng R, Guo X, Kou Y, Xu X, Hong C, Zhang W, et al. Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis. Postgrad Med. 2021;133(6):626–38.
  75. Ding L, Song A, Dai M, Xu M, Sun W, Xu B, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res. 2015 Apr;56(4):920–6.
  76. A L, BG N, PR K. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;
  77. Xu J, Qiu X, Li Y, Sun N, Zhang Y, Shu J. Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population. Medicine (Baltimore). 2020 Sep;99(38):e22037.
  78. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. Vol. 57, Journal of Lipid Research. American Society for Biochemistry and Molecular Biology Inc.; 2016. p. 526–37.
  79. Gonen A, Yang X, Yeang C, Alekseeva E, Koschinsky M, Witztum JL, et al. Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). J Lipid Res. 2020;61(9):1263–70.
  80. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246–55.
  81. Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123–35.
  82. Cobbaert CM, Althaus H, Begcevic Brkovic I, Ceglarek U, Coassin S, Delatour V, et al. Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary/Cross-Sector Collaboration. Clin Chem. 2021 Mar;67(3):478–89.
  83. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996;16(12):1568–72.
  84. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec 1;31(23):2844–53.
  85. Nurmohamed NS, Kaiser Y, Schuitema PCE, Ibrahim S, Nierman M, Fischer JC, et al. Finding very high lipoprotein(a): the need for routine assessment. Eur J Prev Cardiol. 2022 May;29(5):769–76.
  86. Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2022; doi:
  87. Ho JH, Adam S, Liu Y, Azmi S, Dhage S, Syed AA, et al. Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). J Clin Lipidol. 2021;
  88. Tsimikas S. Lipoprotein(a): Novel target and emergence of novel therapies to lower cardiovascular disease risk. Vol. 23, Current Opinion in Endocrinology, Diabetes and Obesity. Lippincott Williams and Wilkins; 2016. p. 157–64.
  89. Cao YX, Jin JL, Guo YL, Sun D, Liu HH, Wu NQ, et al. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis. 2019 Dec;291:27–33.
  90. Lamina C, Kronenberg F. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiol. 2019;4(6):575–9.
  91. Willeit P, Yeang C, Patrick ;, Moriarty M, Tschiderer L, Varvel SA, et al. Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. J Am Hear Assoc J Am Hear Assoc. 2020;9:16318.
  92. Li C, Chen Q, Zhang M, Liu Y, Chu Y, Meng F, et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. BMC Cardiovasc Disord. 2021 Dec;21(1):41.
  93. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000 Dec;46(12):1956–67.
  94. Kostner GM, Ibovnik A, Holzer H, Grillhofer H. Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard. J Lipid Res. 1999 Dec;40(12):2255–63.
  95. Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein (a)-cholesterol: Implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053.
  96. Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees. Curr Opin Lipidol. 2022 Dec;33(6):342–52.
  97. Kronenberg F. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):5–12.
  98. Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022 May;349:110–22.
  99. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020 Jun;41(24):2275–84.
  100. de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 May;29(5):779–92.
  101. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul;371(3):203–12.
  102. Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AFG. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016 Nov;65(11):1664–78.
  103. Artemeva N V., Safarova MS, Ezhov M V., Afanasieva OI, Dmitrieva OA, Pokrovsky SN. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype. Atheroscler Suppl. 2015 May;18:53–8.
  104. Albers JJ, Slee A, O’Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO, et al. Relationship of apolipoproteins A-1 and b, and lipoprotein(a) to cardiovascular outcomes: The aim-high trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol. 2013 Oct;62(17):1575–9.
  105. Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018 Dec;8(1):17887.
  106. Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs. 2018 Mar;78(4):453–62.
  107. Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017 Feb;15(1):22.
  108. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar;139(12):1483–92.
  109. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Jan;75(2):133–44.
  110. Daviglus ML, Ferdinand KC, López JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension S. J Am Heart Assoc. 2021 Jan;10(1).
  111. Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Hear J Suppl. 2020 Nov;22(Supplement_L):L53–6.
  112. Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation. 2020 May;141(20):1608–17.
  113. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 May;141(20):1600–7.
  114. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Mar;382(16):1507–19.
  115. Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. J Clin Lipidol. 2021;15(4):593–601.
  116. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):689–99.
  117. Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, et al. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. J Lipid Res. 2018 Dec;59(12):2397–402.
  118. Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, et al. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770–5.
  119. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 Sep;377(13):1217–27.
  120. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016 Nov;388(10057):2239–53.
  121. Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Vol. 13, Clinical kidney journal. 2020. p. 753–7.
  122. Karwatowska-Prokopczuk E, Clouet-Foraison N, Xia S, Viney NJ, Witztum JL, Marcovina SM, et al. Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. Atherosclerosis. 2021 May;324:102–8.
  123. Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022 Jan;28(1):96–103.
  124. Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. 2022 May;327(17):1679–87.
  125. Kayikcioglu M. LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective. Curr Atheroscler Rep. 2021;23(4).
  126. Safarova MS, Ezhov M V., Afanasieva OI, Matchin YG, Atanesyan R V., Adamova IY, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013 Jan;14(1):93–9.
  127. Khan TZ, Hsu LY, Arai AE, Rhodes S, Pottle A, Wage R, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): A randomized controlled cross-over trial. Eur Heart J. 2017 May;38(20):1561–9.
  128. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–39.
  129. Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem. 1999 Nov;274(48):34111–5.
  130. Akaiek M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002 Sep;48(9):1454–9.
  131. Chasman DI, Shiffman D, Zee RYL, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009 Apr;203(2):371–6.
  132. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis. 1996 Apr;122(1):89–95.
  133. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. J Am Coll Cardiol. 2008 Jul;52(2):124–31.
  134. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006 Sep;8(5):538–54.
  135. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc. 2000 Apr;283(14):1845–52.
  136. Berg K. A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM. Acta Pathol Microbiol Scand. 1963 Nov;59(3):369–82.

Send mail to Author

Send Cancel

Custom technologies based on your needs

  • MongoDB
  • ElasticSearch
  • Redis
  • Solr
  • Memcached